Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 420 Lexington Ave Rm 300 NEW YORK NY 10170-0399 |
| Tel: | N/A |
| Website: | https://scopusbiopharma.com |
| IR: | See website |
| Key People | ||
| Joshua R. Lamstein Chairman of the Board, Principal Executive Officer | Robert J. Gibson Vice Chairman of the Board, Treasurer, Secretary | Alan M. Horsager President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics | Aharon Schwartz Executive Chairman of Scopus BioPharma Israel Ltd |
| Business Overview |
| Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company's Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers. |
| Financial Overview |
| For the six months ended 30 June 2023, Scopus Biopharma Inc revenues was not reported. Net loss decreased 37% to $5.1M. Lower net loss reflects General and administrative - Balancing decrease of 73% to $1.9M (expense), Stock-based Compensation in SGA decrease of 18% to $156K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.38 to -$0.15. |
| Employees: | 13 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | N/A |
| Annual revenue (TTM): | $0.00M as of Jun 30, 2023 |
| EBITDA (TTM): | -$9.34M as of Jun 30, 2023 |
| Net annual income (TTM): | -$8.70M as of Jun 30, 2023 |
| Free cash flow (TTM): | -$3.04M as of Jun 30, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 42,084,264 as of Aug 11, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |